Extended Data Fig. 4: OV-Cmab-hCCL5 improves oncolytic virotherapy in nude mice bearing GBM30 cells. | Nature Cancer

Extended Data Fig. 4: OV-Cmab-hCCL5 improves oncolytic virotherapy in nude mice bearing GBM30 cells.

From: Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity

Extended Data Fig. 4

(a) Survival of GBM30 tumor-bearing nude mice treated with OV-Q1, OV-Cmab-hCCL5, or vehicle control. Survival was estimated by the Kaplan–Meier method and compared by log-rank test (n = 7 mice). (b) Luciferase imaging of GBM30-FFL GBM mice with the indicated treatments 15 and 20 days post tumor implantation.

Source data

Back to article page